• Sulfo-Cy3 Azide: Evidence and Scope

  2026-10-19

  Sulfo-Cy3 azide is a supplier-described, sulfonated fluorescent bioconjugation reagent for aqueous azide–alkyne labeling. The available information supports its identity, optical properties, and intended conceptual scope, but not independent claims about performance, specificity, or biological compatibility.

• Dapansutrile: Evidence and Scope

  2026-10-19

  The available APExBIO listing documents Dapansutrile as a catalog item with SKU B8526, but provides no chemical identifier, mechanism, assay readout, research citation, or product-specific outcome. Accordingly, this record supports catalog provenance only, not claims about molecular action, efficacy, selectivity, or applicability.

• Tetraethylammonium Chloride: Scope and Evidence

  2026-10-18

  The APExBIO product description identifies tetraethylammonium chloride (TEAC) as a tetraethylammonium-ion source and broad potassium-channel pore blocker. It supports a conceptual role in ion-conduction studies and reports vascular, ganglionic, and historical clinical contexts, but it provides no identity-matched research paper, quantitative outcomes, or evidence sufficient to establish channel selectivity, mechanism in a specific tissue, or contemporary clinical efficacy.

• Angiotensin I/II (1-5): Evidence and Scope

  2026-10-17

  A source-attributed overview of the identity, proposed renin–angiotensin system role, product properties, and evidence boundaries for Angiotensin I/II (1-5), without treating supplier claims as validated research findings.

• BODIPY 581/591 C11: Mechanism and Evidence Scope

  2026-10-16

  BODIPY 581/591 C11 is described by APExBIO as a cell-permeable, ratiometric fluorescent probe whose red-to-green spectral shift reports oxidation of its polyunsaturated segment. The product information supports interpretation as a proxy for membrane-associated lipid oxidative stress, but it does not establish direct radical concentrations, antioxidant efficacy, ferroptosis, or performance in any particular biological model.

• When Cholesterol Readouts Change Meaning

  2026-10-16

  Filipin III staining in a 2026 study of PHMG-induced pulmonary fibrosis is informative about a cholesterol-associated cellular readout, but it does not by itself establish total cholesterol burden, cholesteryl ester accumulation, or SOAT1-specific causality. The result changes meaning with the model, comparator, assay principle, and provenance of the material.

• EGCG Nanoparticles and FLASH-RT: What the Study Shows

  2026-10-15

  Xu et al. reported that functionalized EGCG nanoparticles, termed BENPs, enhanced the antitumor effects of FLASH radiotherapy in 4T1 breast-cancer models. The study linked treatment to higher reactive oxygen species, γ-H2AX-associated DNA damage, apoptosis, tumor suppression, and changes in immune-cell populations. These findings support a preclinical radiosensitization hypothesis, but they do not establish clinical efficacy, supplier-specific product performance, or a complete causal mechanism.

• Acacetin: Identity, Mechanism, and Evidence Boundaries

  2026-10-15

  APExBIO describes Acacetin (SKU N2109) as the flavonoid 5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one, with reported applications spanning apoptosis, autophagy, inflammation, cancer biology, neuroscience, and immunology. Because no identity-matched research paper is available here, those applications should be treated as product-context descriptions rather than demonstrated mechanisms, outcomes, or evidence of therapeutic activity.

• When Context Changes the Meaning of γH2AX

  2026-10-14

  A γH2AX signal can indicate an activated DNA-damage response, but its scientific meaning depends on the model, comparator, timing, and endpoint surrounding it. The reported BENPs–FLASH-RT study illustrates how the same molecular readout can support a radiosensitization hypothesis without, by itself, establishing clinical benefit, selective tumor killing, or a causal immune mechanism.

• LLY-507 and SMYD2: Evidence in Kidney Fibrosis

  2026-10-14

  A 2023 study links pharmacological SMYD2 inhibition with reduced fibrosis and inflammation in a cisplatin-induced chronic kidney disease model. The findings support SMYD2 as a candidate mechanistic regulator, but they do not establish clinical efficacy, broad applicability across chronic kidney disease, or definitive target-specific causality. Commercial claims about LLY-507’s selectivity and anticancer activity should be distinguished from peer-reviewed evidence.

• EGCG Nanoparticles and FLASH-RT: What the Study Shows

  2026-10-13

  A preclinical study reports that functionalized EGCG nanoparticles may sensitize 4T1 tumors to FLASH radiotherapy by increasing radiation-associated damage and altering immune responses. The evidence is promising but remains limited to cell and mouse models, with important uncertainties about mechanism, safety, and clinical applicability.

• Golgi Stress and PR Suppression in Breast Cancer

  2026-10-13

  The supplied 2026 study reports that CA800-PR, a tumor-targeted heptamethine cyanine dye, was associated with Golgi fragmentation, progesterone-receptor suppression, apoptosis, and inflammatory immune changes in cellular and xenograft models. These findings are hypothesis-generating rather than clinical evidence and should not be conflated with the distinct imaging role of Golgi-Tracker Green.

• Tofacitinib Citrate and Endothelial Inflammation

  2026-10-12

  A 2025 in vitro comparison found that JAK inhibitors consistently reduced inflammatory IL-6 release in cytokine-stimulated human endothelial cells, but their effects on adhesion, coagulation, and cell survival differed. The findings clarify a mechanistic research context for Tofacitinib citrate while remaining limited in their ability to predict cardiovascular outcomes in patients.

• hUC-MSCs, β-NGF and Postoperative Cognition

  2026-10-12

  A 2026 mouse study reports that human umbilical cord mesenchymal stem cells improved surgery-associated cognitive impairment and links the effect to β-NGF, TrkA, STMN2/NMNAT2, SARM1 and NF-κB signaling. The findings are mechanistically suggestive but remain preclinical and do not establish clinical efficacy or safety.

• PA-Ψ-seq Maps Pseudouridine on HIV-1 RNA

  2026-10-10

  Martinez Campos et al. introduced and validated PA-Ψ-seq, an antibody-based approach for locating pseudouridine residues across cellular and HIV-1 transcripts. The study identified transcript-specific contributions from several host pseudouridine synthases but found that HIV-1-associated Ψ sites were not altered by loss of PUS1, PUS7, or TRUB1/PUS4, leaving the dominant source of mRNA pseudouridylation unresolved.

8531 records 1/569 page Next 12345 下5页 Last page